Evaluation of Two Different Non-invasive Techniques to Monitor the Clearance of Actinic Keratosis Lesions
Actinic Keratosis
About this trial
This is an interventional diagnostic trial for Actinic Keratosis focused on measuring Aldara, Actinic Keratosis
Eligibility Criteria
Inclusion Criteria: At least 5 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions Free of any significant findings (e.g tattoos) in the potential application site area. Willing to discontinue sun-tanning and use of sunbed/sun parlour use Willing to stop use of moisturisers, body oils, and over the counter retinol products or products containing alpha or beta hydroxyacids in the treatment or surrounding area. Willing ot withhold sunscreen and/or moisturiser use for 24 hours prior to each clinical assessment Exclusion Criteria: Evidence of unstable or uncontrolled clinically significant medical condition. Any dermatological disease and or condition in the treatment of the surrounding area that may be exacerbated by treatment with imiquimod. Currently participating in another clinical study or have completed another study within an investigational drug within the past 30 days. Have active chemical dependency or alcoholism Have know allergies to any excipient or study cream Have received previous treatment with imiquimod for any indication within the treatment area. Known to be affected by porphyria
Sites / Locations
- Hopital L'Archet 2
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
250mg of Imiquimod cream application once daily 3 times per week.
250mg vehicle cream for application once daily 3 times per week.